365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Dyson A, Aberg J, Molina J, Cassetti I, Kozal M, Treviño-Pérez S, Latiff G, Lalezari J, Pialoux G, Li B, Prakash M, Clark A, Tenorio A, Pierce A, Lataillade M. 365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment. Open Forum Infectious Diseases 2023, 10: ofad500.435. PMCID: PMC10676856, DOI: 10.1093/ofid/ofad500.435.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1T-cell countsVirologic response ratesCells/mm3Randomized cohortHIV-1Response rateBL CD4Viral loadDisease characteristicsTreatment optionsAdvanced HIV-1Current ARV regimenPlacebo-controlled periodTreatment-experienced peopleT-cell increaseLimited treatment optionsLong-term efficacyOverall response rateLow response rateBackground therapyContinuous CD4Suppressive regimensWeek 96Virologic response